Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Aug 24, 2022 3:39am
159 Views
Post# 34916186

RE:Share Buybacks & Use of Cash

RE:Share Buybacks & Use of Cash
longrun86 wrote: I will start out by saying that this post contains "speculation" on my part.

An interesting point was made with the release of the Q2 results. Knight had made no further purchases under the NCIB. While the share price had appreciated somewhat, I don't think that it moved too far out of "value" territory.

Given the comments made by Management and the strategic use of capital, I believe that Management has identified better opportunities for the deployment of the current cash balance through both organic and in-organic opportunities. Time will reveal if this is in fact true.

The other potential view is that they view the "investment & loan" portfolio as requiring a bit more time to play out and reach maturity where they can realize the value and convert to cash.

I look forward to seeing Knight grow and make strategic investments in the coming quarters.

LR


It's possible they've identified some bigger opportunities - perhaps even likely. With that said, here are some points that I believe affect the management's logic for buying back shares:

+ Potential opportunities for Mexico and/or Canada in the horizon. Something could have come up in Brazil or Colombia as well.
+ Lower cash balance than before. Given the current share price (=can't sell shares to the market), we need to maintain a certain level of cash just in case opportunities pop up.
+ Increases in working capital/inventory for Q3 and Q4 mean that cash flow from operations is restricted for the remainder of the year. (On the other hand, we did get the $5.9M settlement fee + the US$5.5M Synergy loan reaches maturity in 2022, so there's some money coming in.)
+ Even if we don't have huge deals in the horizon, upfront payments for new in-licensed drugs can still require money in the tens of millions. IF my calculations are correct, we spent $30M+ on these types of deals in H1/22.
+ I doubt this management wants to take the risk to be desperate for cash at any point.

With that said, they did launch the NCIB. In other words, the buybacks will continue should we reach a certain price level... but I'd guess the return has to be even higher than before for that to happen, given the conditions we're in.

Hopefully the main reason is opportunities in Mexico and/or Canada. :)
<< Previous
Bullboard Posts
Next >>